Clinical Trials

Clinical Trials

Pasithea is conducting two clinical trials for PAS-004. You can learn about these trials by clicking on the links below.

PAS-004 in Patients With Advanced Solid Tumors

Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in Patients With MAPK Pathway-driven Advanced Solid Tumors With a Documented RAS, NF1, or RAF Mutation or Patients Who Have Failed BRAF/MEK Inhibition.

Learn more at clinicaltrials.gov

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Phase 1/1b multicenter, open-label, dose escalation trial of PAS-004 in adult patients with symptomatic and inoperable, incompletely resected, or recurrent NF1-PNs

Learn more at clinicaltrials.gov